AstraZeneca advances scientific leadership in cardiovascular and renal diseases with over 60 abstracts collectively at ASN Kidney Week 2022 and AHA Scientific Sessions 2022

31 October 2022 9:00 GMT
 

Depth and breadth of data underscore commitment to addressing areas of high unmet
need in cardiorenal and rare nephrology diseases
 

AstraZeneca will present over 60 abstracts across its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio and from Alexion, AstraZeneca’s Rare Disease group, at the American Society of Nephrology (ASN) Kidney Week from 3-6 November 2022 and the American Heart Association (AHA) Scientific Sessions occurring 5-7 November 2022.

With robust science across both medical congresses, AstraZeneca demonstrates its ambition to fundamentally transform cardiorenal care and advance patient outcomes by unravelling the underlying causes of disease, developing diagnostic strategies and delivering innovative, life-changing solutions for the millions of people affected by this interconnected spectrum of diseases. Additionally, Alexion will present data highlighting scientific advancements that further the understanding of complement inhibition in the treatment of rare nephrology diseases.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Scientific advances are revealing the connection between cardiovascular, renal and metabolic diseases, helping to drive earlier diagnosis and opportunities for integrated treatment approaches. We look forward to sharing insights across our portfolio, including our early science targeting specific disease drivers and data from both the DELIVER and DAPA-CKD Phase III trials which build on the science demonstrating the unique cardiorenal protection and mortality benefit of Farxiga.”

Farxiga in heart failure (HF)setting a new standard in HF management
New late-breaking data from the DELIVER Phase III trial presented at AHA assess the effects of Farxiga on health status, on patients with recurrent cardiac events, the impact based on use of other therapies, on gender or race and more1-5. These data reinforce the joint 2022 guidelines issued by AHA, the American College of Cardiology (ACC) and the Heart Failure Society of America (HFSA), recommending earlier diagnosis and earlier initiation of guideline-directed medical treatment in patients with HF6. Altogether, the pooled analysis from the Phase III DELIVER and DAPA-HF trials underpins the role of Farxiga in clinical practice as a treatment that can be initiated right away while waiting for ejection fraction (EF) to be measured and that showed mortality benefit across the full EF range7.

Farxiga in chronic kidney disease (CKD)reinforcing leadership in CKD
New subgroup data from the DAPA-CKD Phase III trial assess effect in patients with microalbuminuria, how Farxiga use impacts hospital admissions and healthcare utilisation and highlights AstraZeneca’s commitment to help prevent or slow the progression of CKD in this large patient population8-10. These data presented at ASN also support recent updates to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which highlight the need for preventive treatment strategies that reduce the risk of adverse kidney and cardiovascular (CV) outcomes11.

REVEAL-CKD – emphasising the need for earlier diagnosis
REVEAL-CKD data also shed light on the importance of earlier diagnosis of CKD, with the prevalence of undiagnosed CKD continuing to rise. REVEAL-CKD further demonstrated that once a diagnosis was made, patients did receive timely CKD monitoring and management of their disease, leading to patient benefits12.

Lokelma – advancing proactive hyperkalaemia (HK) management
New Lokelma data from the comprehensive CRYSTALIZE evidence programme, which is poised to disrupt the current management of HK, highlight the common and detrimental effects of renin-angiotensin-aldosterone system inhibitors (RAASi) down titration and/or discontinuation, resulting in suboptimal care of patients with CKD and/or HF, as well as patient preference amongst potassium (K+) binder treatments13,14. The 2020 and 2021 KDIGO15,16, 2021 European Society of Cardiology (ESC)17 and 2022 AHA/ACC/HFSA guidelines6 recognise novel K+ binders like Lokelma as an important management option to optimise RAASi therapy, a group of medicines key to slowing progression and reducing mortality risk in patients with CKD and/or HF.

Compass Programme – highlighting the importance of earlier diagnosis in hereditary amyloid transthyretin amyloidosis (ATTR)
Findings from the Compass Programme provide important insights on genetic testing for ATTR. Amyloidosis is progressive and may be systemic, affecting different organs within the body (i.e., heart, kidneys, peripheral nerves)18.

Amyloidosis diseases can be complex, difficult to diagnose and, in many cases, fatal if left untreated19-21. AstraZeneca, in partnership with Ionis, and Alexion, are advancing multiple assets and novel science in amyloidosis, including treatments for ATTR, cardiomyopathy (CM) and polyneuropathy (PN), as well as amyloid light chain (AL) amyloidosis.

Rare nephrology – expanding our leadership in complement inhibition
Alexion will present an analysis from the global atypical hemolytic uremic syndrome (aHUS) registry involving long-term outcomes in patients who are treated with Soliris, a characterisation of patients with thrombotic microangiopathy and triggering or associated events from the aHUS registry, as well as a tool (PLASMIC score) that may aid in the diagnosis of aHUS22-24.

Alexion is also expanding its focus in rare nephrology with multiple assets in its clinical development programmes – including Ultomiris (a C5 inhibitor) and ALXN2050 (an oral factor D inhibitor) – which are being investigated as potential treatments for proliferative lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN). The presentations at ASN, which include clinical trial and real-world data across several therapeutic areas, will help to advance the understanding of these rare nephrology diseases and foster scientific exchange22-26.

AstraZeneca abstracts at ASN Kidney Week 2022 include:

Lead author

Abstract title

Presentation details

Farxiga

Schechter M

Dapagliflozin effect on hospital admissions in patients with chronic kidney disease: A post hoc analysis of the DAPA-CKD trial

Oral Presentation

CKD: Clinical Outcomes, Trials, Mechanistic Insights

November 4, 2022 16:30-18:00

Session Room: W307

Vart P

Efficacy and safety of dapagliflozin in black vs. white patients with CKD

Poster

CKD: Clinical Trials and Pharmacoepidemiology

November 5, 2022 10:00-12:00

Poster #: SA-PO889

Vart P

Effects of dapagliflozin on anaemia in patients with or without type 2 diabetes: A pre-specified analysis of the DAPA-CKD trial

Oral Presentation

High-Impact CKD Potpourri: Something for Everyone

November 5, 2022 16:30-18:00

Session Room: W307

Jongs N

Consistent benefits of dapagliflozin on kidney endpoints defined by different eGFR thresholds: A prespecified analysis from DAPA-CKD

Poster

CKD: Clinical Trials and Pharmacoepidemiology

November 5, 2022 10:00-12:00

Poster #: SA-PO886

Davis J

Extrapolation of DAPA-CKD trial endpoints in a broad urine albumin creatinine ratio population

Poster

CKD: Clinical Trials and Pharmacoepidemiology

November 5, 2022 10:00-12:00

Poster #: SA-PO888

McEwan P

Translating the findings of DAPA-CKD to reductions in healthcare resource utilization from a global perspective

Poster

CKD: Clinical Trials and Pharmacoepidemiology

November 5, 2022 10:00-12:00

Poster #: SA-PO887

Wittbrodt E

Early dapagliflozin utilization for CKD treatment in the United States

Poster

CKD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO855

Leon SJ

Association between CKD progression and heart failure: A retrospective cohort study

Poster

Hypertension and CVD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO630

Heerspink HJ

Effects of dapagliflozin in patients without diabetes and with microalbuminuria: An exploratory analysis from the DAPA-CKD trial

Poster

CKD: Clinical Trials and Pharmacoepidemiology

November 5, 2022 10:00-12:00

Poster #: SA-PO885

Sisk R

A global validation of a minimal-resource pre-screening model for reduced kidney function in patients with type 2 diabetes

Poster

Diabetic Kidney Disease: Clinical - II

November 3, 2022 10:00-12:00

Poster #: SA-PO283

Shoichi M   

Impact of urinary protein examination on early diagnosis of CKD: A nationwide hospital-based observational study in Japan, REAL-CKD

Poster

CKD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO883

Heerspink H

Correlation between albuminuria and echocardiographic (echo) abnormalities in individuals with type 2 diabetes (T2D): Insights from the Take Care of Me (TCoM) program

Poster

Diabetic Kidney Disease: Clinical

November 3, 2022 10:00-12:00

Poster #: TH-PO233

 

McCausland F

Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: Results from DELIVER

Poster

Late-Breaking Clinical Trials (Posters)

November 3, 2022 10:00-12:00
Poster #: TH-PO992
Location: West Exhibit Hall E

Dapagliflozin/Metformin

Santos-Araúijo C

Cardiorenal syndrome and death risk in patients with heart failure or chronic kidney disease: An urgent call for action

Poster

Hypertension and CVD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO628

Santos-Araúijo C

Cardiorenal syndrome and kidney disease progression in patients with heart failure or CKD: An urgent call for action

Poster

Hypertension and CVD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO627

Verinurad (RDEA3170)

Halperin Kuhns V

Urate regulates mitochondrial function in a URAT1 dependent manner in renal epithelial cells

Poster

CKD: Pathobiology

November 4, 2022 10:00-12:00

Poster #: FR-PO996

Lokelma

Wheeler D

APPETIZE: Palatability of and preference for potassium binders in patients with CKD and hyperkalaemia

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO552

Ni Z

DIALIZE China: A phase 3b study to reduce pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate in Chinese subjects

Oral Presentation

Dialysis: Patient-Centered Interventions and Outcomes

November 3, 2022 16:30-18:00

Session Room: W414

Hsia J

A prospective, real-world evidence study of hyperkalaemia management decision making: Design of the TRACK study

Abstract Supplement

Abstract published in ASN's 2022 Abstract Supplement, available here: http://www.asn-online.org/abstracts/

Bakris G

Effects of sodium zirconium cyclosilicate (SZC) on CKD progression: Rationale and design of the phase 3 STABILIZE-CKD trial

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO550

Ni Z

Hyperkalaemia disease burden and dialysis patterns in Chinese haemodialysis patients: An interim analysis of the Precede-K study

Poster

Hemodialysis and Frequent Dialysis: Potpourri

November 5, 2022 10:00-12:00

Poster #: SA-PO311

Zhao X

Hyperkalaemia prevalence, practice pattern and mortality in Chinese haemodialysis patients: Visualize-HD study

 

Abstract Supplement

Abstract published in ASN's 2022 Abstract Supplement, available here: http://www.asn-online.org/abstracts/

Streja E

Impact of hyperkalaemia on mortality in patients with advanced kidney disease with or without haemodialysis: Implications for deferring hemodialysis initiation under value-based models

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO544

Rastogi A

Persistent reduction in RAASi therapy following an episode of hyperkalaemia

 

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO546

Zhou H

Recurrent hyperkalaemia and renin-angiotensin-aldosterone system inhibitor (RAASi) down-titration in a US integrated healthcare system

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO547

An J

Cardiorenal and mortality outcomes associated with renin-angiotensin-aldosterone system inhibitor (RAASi) discontinuation after new-onset hyperkalaemia

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO548

Marmol F

Renal adaptation to increased fecal potassium excretion by sodium zirconium cyclosilicate

 

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Basic

November 3, 2022 10:00-12:00

Poster #: TH-PO305

Marmol F

Sodium zirconium cyclosilicate (SZC) binds ammonium (NH4+) in the GI tract

 

Poster

Fluid, Electrolyte, and Acid-Base Disorders: Basic

November 3, 2022 10:00-12:00

Poster #: TH-PO304

Eichiro K

Impact of chronic potassium binder treatment on clinical outcome in patients with hyperkalaemia: A nationwide hospital-based cohort study

Poster
Fluid, Electrolyte, and Acid-Base Disorders: Clinical

November 4, 2022 10:00-12:00

Poster #: FR-PO549

General/Early CVRM

Lal M

Therapeutic blocking of NPRC, a podocyte-expressed target, is kidney protective in ZSF1 rats

Poster

Glomerular Diseases: Podocyte Biology

November 4, 2022 10:00-12:00

Poster #: FR-PO696

Svangård N

Toward a model-based patient pre-selection tool to identify suspected undiagnosed albuminuria using electronic health records

 

Abstract Supplement

Abstract published in ASN's 2022 Abstract Supplement, available here: http://www.asn-online.org/abstracts/

Seth A

TWEAK-Fn14 signalling in mesangial cells drives intrarenal inflammation during CKD progression

 

Poster

CKD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO891

Carracedo M

APOL1 promotes endothelial cell activation beyond the glomerulus

Oral Presentation

Glomerular Diseases: From Bench to Bedside

November 4, 2022 16:30-18:00

Session Room: W414

Acoba D

Kidney ‘pathway orphan’ genes as an untapped source of novel biology and disease understanding

Abstract Supplement

Abstract published in ASN's 2022 Abstract Supplement, available here: http://www.asn-online.org/abstracts/

Woollard KJ

Investigating lysozyme as a mediator of tubular epithelial inflammation: An example of CKD knowledge graph target discovery and validation

Poster

CKD: Pathobiology - I

November 4, 2022 10:00-12:00

Poster #: FR-PO1008

 

Tomaz D

NLRP3 inflammasome inhibition decreases NETosis in AKI

Poster

AKI: Mechanisms - II

November 4, 2022 10:00-12:00

Poster #: FR-PO167

Zibotentan (ZD4054)

Ahlström C

SGLT2 inhibition mitigates intravascular fluid retention driven by an endothelin A receptor antagonist

 

Abstract Supplement

Abstract published in ASN's 2022 Abstract Supplement, available here: http://www.asn-online.org/abstracts/

REVEAL-CKD

Tangri N

REVEAL-CKD: Management and monitoring of patients with CKD stage 3 in France, Germany, Italy, Japan and the United States

Poster

CKD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO889

Tangri N

REVEAL CKD: Estimated glomerular filtration rate (eGFR) decline before and after a CKD diagnosis among patients with CKD stage 3

Poster

CKD: Epidemiology, Risk Factors, Prevention

November 3, 2022 10:00-12:00

Poster #: TH-PO888

Global aHUS Registry

Siedlecki A

Characterization of patients with thrombotic microangiopathy and triggering/associated events: A Global aHUS Registry analysis

Poster

Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1]

November 3, 2022 10:00-12:00

Poster #: TH-PO500

Greenbaum L

Long-term outcomes in eculizumab-treated patients enrolled in the global aHUS registry

Poster

Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1]

November 3, 2022 10:00-12:00

Poster #: TH-PO502

Soliris and Ultomiris

Uriol M

PLASMIC score to aid diagnosis of atypical hemolytic uremic

syndrome: A post-hoc analysis of data from C5 inhibitor trials

Poster

Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1]

November 3, 2022 10:00-12:00

Poster #: TH-PO501

Ultomiris

Garlo K

A phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN)

Poster

November 3, 2022 10:00-12:00

Poster #: INFO34

 

ALXN2050

Garlo K

A phase 2 study evaluating the efficacy and safety of ALXN2050, a complement factor D inhibitor, in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN)

Poster

November 3, 2022 10:00-12:00

Poster #: INFO33

 

ASN Kidney Week 2022 abstracts are available online.

 

AstraZeneca abstracts at AHA Scientific Sessions 2022 include:

Lead author

Abstract title

Presentation details

Farxiga

Jhund P

First and repeat episodes of worsening heart failure in patients with heart failure with mildly reduced and preserved ejection fraction: An analysis of Deliver

Oral Presentation
In-depth and Fresh Look in Heart Failure Trials

November 6, 2022 8:36-8:46

Session Room: N230B

Bhatt A

Impact of Coronavirus Disease-2019 on participants in DELIVER

Oral Presentation

Evolving Science in COVID-19

November 7, 2022 8:20-8:30 Session Room: Main Event III

Kosiborod M

The effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and mildly reduced or preserved ejection fraction: Results from the DELIVER Trial

Oral Presentation

A Second Look at Practice-Changing Heart Failure Trials

November 7, 2022 11:00-11:08

Session Room: Main Event II

Yang M

Baseline characteristics, outcomes, and treatment response to dapagliflozin in patients treated with an MRA or ARNI in DELIVER

Oral Presentation

A Second Look at Practice-Changing Heart Failure Trials

November 7, 2022 11:08-11:16 Session Room: Main Event II

Wang X

Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure

Oral Presentation

A Second Look at Practice-Changing Heart Failure Trials

November 7, 2022 11:16-11:24

Session Room: Main Event II

Butt J

Differences in clinical characteristics, outcomes, and treatment response to dapagliflozin across the range of ejection fraction in Black and White patients with heart failure: A pooled analysis of DAPA-HF and DELIVER

Oral Presentation

A Second Look at Practice-Changing Heart Failure Trials

November 7, 2022 11:24-11:32

Session Room: Main Event II

Schechter M

The effect of dapagliflozin on hospital admissions in patients with type 2 diabetes: Post hoc analysis of the DECLARE-TIMI 58 trial

Virtual Poster - Available November 5-7, 2022

Poster #: VP345

Bozkurt B

Use of guideline-directed medical therapies after hospitalization for heart failure: Real-world insights from EVOLUTION HF

Poster

Drugs, Drugs and More Drugs in Heart Failure: Impact on Outcomes

November 6, 2022 10:30-11:30

Poster #: SU2153

Berg D

Serial assessment of cardiac biomarkers and risk of cardiovascular death or hospitalization for heart failure in DECLARE-TIMI 58

Oral Session

Advances in Diabetes and Heart Failure: From Bench to Bedside

November 6, 2022 15:54-16:04

Session Room: N231

Chung-Lieh H

Clinical utilization of natriuretic peptide levels independent of WATCH-DM score for heart failure prediction in a large-scale Asian diabetic population - A multi-center cohort study

Virtual Poster - Available November 5-7, 2022

Poster #: VP347

Tsubota H

Machine learning models to predict development of CKD and/or HF in early stages of type 2 diabetes patients

Poster

Predicting Incident Diabetes and Its Complications

November 6, 2022 10:30-11:30

Poster #: SU3000

Kosiborod M

Prevalence and correlates of echocardiographic abnormalities in type 2 diabetes: Insights from iCaReMe Global Registry

Poster

Mechanisms and Treatments for Heart Failure in Diabetes

November 6, 2022 10:30-11:30

Poster #: SU3012

Gupta K

Health status outcomes by race in patients treated with sodium-glucose cotransporter 2 inhibitors: A pooled patient-level meta-analysis of CHIEF-HF, DEFINE-HF, and PRESERVED-HF

Moderated Poster

November 7, 2022 10:00-10:05

Poster #: MP186

Brilinta

Small A

Development of a novel polygenic risk score to predict risk of aortic stenosis events

Oral Presentation

November 6, 2022 12:10-12:15

Poster #: 554

Ohman E

Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischemic events after PCI: Results from the TWILIGHT - Recurrent Events sub-study

Oral Presentation

Optimal Management post PCI/ACS

November 7, 2022 10:02-10:12

Session Room: Main Event III

Eplontersen

Bhatt K

Genetic testing for hereditary amyloid transthyretin amyloidosis: Insights from the Compass Program

Moderated Poster

November 5, 2022 11:00-12:00

Poster #: SA2110

Exenatide

Ostroff R

Cardiometabolic disease protein signatures and response to GLP-1 receptor agonist in the EXSCEL clinical trial

Rapid Fire Oral Presentation

Understanding and Modifying Cardiovascular Risk in Diabetes

November 7, 2022 13:00-13:05

Session Room: Zone 3, Science & Technology hall, Level 3

Peters AE

Proteomic pathways across ejection fraction categories in heart failure: an EXSCEL substudy

Poster

Biomarkers in Heart Failure: Prognostic Indicators and Mechanistic Research

November 6, 2022 15:45-16:45

Poster #: SU2183

Edmonston D

Metabolic profiles identify distinct cardiorenal risk factors in people with diabetes mellitus: Insights from the EXSCEL trial

Oral Presentation

Intersection of Kidney and Heart Failure - Biomarkers, Treatment, and Outcomes in Patients with Cardiorenal Disease

November 6, 2022 17:00-17:10

Session Room: S101B

Early R&D

Kardassis D

Safety, pharmacokinetics, and pharmacodynamics of AZD3366 alone and in combination with aspirin and ticagrelor in healthy subjects

Virtual Poster - Available November 5-7, 2022

Poster #: VP26

Varma V

Identification of response biomarkers and signaling pathways associated with the LOX-1 blockade by MEDI6570 in type 2 diabetes

Virtual Poster - Available November 5-7, 2022

Poster #: VP6

Hofherr A

The PCSK9-targeted antisense oligonucleotide AZD8233 reduces LDL-C, ApoB, and Lp(a) in patients with dyslipidemia on statin treatment - Data from the phase 2b ETESIAN study

Virtual Poster - Available November 5-7, 2022

Poster #: VP112

AHA Scientific Sessions 2022 abstracts are available online.

Notes

AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection and improving outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CV health for millions of patients worldwide.

Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit ulzb.net and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.


References

1. Kosiborod MN, et al. The effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and mildly reduced or preserved ejection fraction: results from the DELIVER Trial. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.

2. Jhund P, et al. First and repeat hospitalizations for heart failure in patients with heart failure with mildly reduced and preserved ejection fraction: An analysis of DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.

3. Jhund P, et al. Baseline characteristics, outcomes, and treatment response to dapagliflozin in patients treated with an MRA or ARNI in DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.

4. Solomon S, et al. Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: a pooled analysis of DAPA-HF and DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.

5. Butt J, et al. Differences in clinical characteristics, outcomes, and treatment response to dapagliflozin across the range of ejection fraction in Black and White patients with heart failure: A pooled analysis of DAPA-HF and DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.

6. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.

7. Jhund P, et al [Internet]. Dapagliflozin and outcomes across the range of ejection fraction in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. Nature Medicine. [cited 2022 Oct 11] Available from: http://www.nature.com/articles/s41591-022-01971-4

8. Davis J, et al. Extrapolation of DAPA-CKD trial endpoints in a broad urine albumin creatinine ratio population. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

9. Schechter M, et al. Dapagliflozin effect on hospital admissions in patients with chronic kidney disease: A post hoc analysis of the DAPA-CKD trial. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

10. McEwan P, et al. Translating the findings of DAPA-CKD to reductions in healthcare resource utilization from a global perspective. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

11. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group [Internet]. KIDGO 2022 clinical practice guideline for diabetes management in chronic kidney disease [cited 2022 Oct 11]. Available from: KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf.   

12. Tangri N, et al. REVEAL-CKD: Management and monitoring of patients with CKD stage 3 in France, Germany, Italy, Japan, and the USA. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA

13. Ni Z, et al. DIALIZE China: A phase 3b study to reduce pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate in Chinese subjects. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

14. Wheeler D, et al. APPETIZE: Palatability of and preference for potassium binders in patients with chronic kidney disease and hyperkalaemia. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

15. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int Suppl. 2020;98:S1-S115. 

16. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S):S1-S87. 

17. European Society of Cardiology [Internet]. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [cited 2022 Oct 11]. Available from: http://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehab368.

18. Bhatt K, et al. Genetic testing for hereditary amyloid transthyretin amyloidosis: Insights from the Compass Program. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

19. NORD [Internet]. Amyloidosis [cited 2022 Oct 11]. Available from: http://rarediseases.org/rare-diseases/amyloidosis/

20. Leukaemia and Lymphoma Society [Internet]. Amyloidosis fact [cited 2022 Oct 11]. Available from: http://llscorp.stg.lls.org/sites/default/files/2021-05/Amyloidosis_FINAL.pdf

21. Cedars Sinai [Internet]. Amyloidosis [cited 2022 Oct 11]. Available from: http://www.cedars-sinai.org/health-library/diseases-and-conditions/a/amyloidosis.html

22. Siedlecki A, et al. Characterization of patients with thrombotic microangiopathy and triggering/associated events: A global aHUS registry analysis. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

23. Greenbaum L, et al. Long-term outcomes in eculizumab-treated patients enrolled in the global aHUS registry. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

24. Uriol M, et al. PLASMIC score to aid diagnosis of aHUS: A post-hoc analysis of data from C5 inhibitor trials. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

25. Garlo K, et al. A phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN). Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.

26. Garlo K, et al. A phase 2 study evaluating the efficacy and safety of ALXN2050, a complement factor D inhibitor, in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN). Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.


tags

  • Corporate and financial